Inactive Instrument

Highlights MaxCyte, Inc. London S.E.

Equities

MXCN

USU575801258

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

MaxCyte inks deal with Legend Biotech for tech supply	May. 22	AN
MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program	May. 22	MT
MaxCyte, Inc. Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development	May. 22	CI
MaxCyte Shares Rise Sharply After Q1 Results Beat	May. 08	MT
MaxCyte shares rise amid double-digit revenue increase	May. 08	AN
Earnings Flash (MXCT.L) MAXCYTE Posts Q1 Revenue $11.3M	May. 08	MT
Earnings Flash (MXCT.L) MAXCYTE Reports Q1 Loss $-0.09	May. 08	MT
MaxCyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Earnings Flash (MXCT) MAXCYTE Reports Q1 Revenue $11.3M, vs. Street Est of $7.5M	May. 07	MT
Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024	May. 07	CI
MaxCyte inks deal with Be Bio; Orcadian firms farmout	Apr. 02	AN
MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines	Apr. 02	CI
MaxCyte loss widens in 2023 as core revenue declines 25%	Mar. 13	AN
MaxCyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
MaxCyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12	CI
Earnings Flash (MXCT) MAXCYTE Reports Q4 Revenue $15.7M, vs. Street Est of $15.1M	Mar. 12	MT
MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024	Mar. 12	CI
EARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profit	Mar. 05	AN
MaxCyte Reaffirms Fiscal 2023 Revenue Guidance	Mar. 04	MT
MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024	Mar. 04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights MaxCyte, Inc. London S.E.

Equities

MXCN

USU575801258

Highlights

Filters